503
Participants
Start Date
May 31, 2006
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
Nadroparin
Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
GSK Investigational Site, Ljubljana
GSK Investigational Site, Brussels
GSK Investigational Site, Budapest
GSK Investigational Site, Budapest
GSK Investigational Site, Brussels
GSK Investigational Site, Budapest
GSK Investigational Site, Antwerp
GSK Investigational Site, Törökbálint
GSK Investigational Site, Brasschaat
GSK Investigational Site, Liège
GSK Investigational Site, Golnik
GSK Investigational Site, Roeselare
GSK Investigational Site, Győr
GSK Investigational Site, Aalst
GSK Investigational Site, Marseille
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Genoa
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Bergamo
GSK Investigational Site, Pavia
GSK Investigational Site, Bremen
GSK Investigational Site, Hanover
GSK Investigational Site, Padua
GSK Investigational Site, Giessen
GSK Investigational Site, Greifenstein
GSK Investigational Site, Fulda
GSK Investigational Site, Magdeburg
GSK Investigational Site, Düsseldorf
GSK Investigational Site, Saint-Priest-en-Jarez
GSK Investigational Site, Herne
GSK Investigational Site, Essen
GSK Investigational Site, Florence
GSK Investigational Site, Cologne
GSK Investigational Site, Mainz
GSK Investigational Site, Lille
GSK Investigational Site, Béthune
GSK Investigational Site, Clermont-Ferrand
GSK Investigational Site, Chieti Scalo
GSK Investigational Site, Strasbourg
GSK Investigational Site, Mannheim
GSK Investigational Site, Heidelberg
GSK Investigational Site, Lyon
GSK Investigational Site, Pierre-Bénite
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Planegg
GSK Investigational Site, Campobasso
GSK Investigational Site, Augsburg
GSK Investigational Site, Ebensfeld
GSK Investigational Site, Bad Berka
GSK Investigational Site, Moscow
GSK Investigational Site, Arkhangelsk
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Voronezh
GSK Investigational Site, Kazan'
GSK Investigational Site, Samara
GSK Investigational Site, Orenburg
GSK Investigational Site, Kirov
GSK Investigational Site, Omsk
GSK Investigational Site, Toronto
GSK Investigational Site, Brno
GSK Investigational Site, Prague
GSK Investigational Site, Prague
GSK Investigational Site, Prague
GSK Investigational Site, Prague
GSK Investigational Site, Příbram
GSK Investigational Site, Halle
GSK Investigational Site, Almelo
GSK Investigational Site, Amsterdam
GSK Investigational Site, Amsterdam
GSK Investigational Site, Amsterdam
GSK Investigational Site, Breda
GSK Investigational Site, Delft
GSK Investigational Site, Eindhoven
GSK Investigational Site, Enschede
GSK Investigational Site, Nieuwegein
GSK Investigational Site, Nijmegen
GSK Investigational Site, Rotterdam
GSK Investigational Site, Sittard
GSK Investigational Site, The Hague
GSK Investigational Site, Winterswijk
GSK Investigational Site, Zwolle
GSK Investigational Site, Bialystok
GSK Investigational Site, Krakow
GSK Investigational Site, Lubin
GSK Investigational Site, Olsztyn
GSK Investigational Site, Olsztyn
GSK Investigational Site, Warsaw
Lead Sponsor
GlaxoSmithKline
INDUSTRY